'''交叉呈遞'''（Cross-presentation）是一些[[抗原呈遞細胞|抗原呈遞細胞]]具有能將外源型抗原使用MHC1類分子呈遞至[[細胞毒性T細胞|CD8+ T細胞]]（細胞毒性T細胞，CTL）的能力。交叉呈遞可以造成交叉致敏（Cross-priming），激活初始[[細胞毒性|細胞毒性]]CD8+ T細胞<ref>{{cite journal|url=http://www.nature.com/ni/journal/v7/n4/full/ni0406-363.html|title=Cross-priming|last=Bevan|first=Michael J.|journal=Nature Immunology|publisher=Nature Publishing Group|volume=7|pages=363–365|doi=10.1038/ni0406-363|year=2006|pmid=16550200|issue=4|access-date=2016-10-30|archive-date=2009-04-16|archive-url=https://web.archive.org/web/20090416044208/http://www.nature.com/ni/journal/v7/n4/full/ni0406-363.html|dead-url=no}}</ref>。交叉呈遞對於免疫系統抵抗不侵染[[抗原呈遞細胞|抗原呈遞細胞]]（APC）或能削弱[[树突状细胞|树突状细胞]]（DC）的大部分腫瘤和病毒來說至關重要<ref name="Heath">{{cite journal | last1 = Heath | first1 = WR | last2 = Carbone | first2 = FR | year = 2001 | title = Cross-presentation in viral immunity and self-tolerance | url = | journal = Nat Rev Immunol | volume = 1 | issue = 2| pages = 126–34 | doi=10.1038/35100512| pmid = 11905820 }}</ref><ref>{{cite journal | last1 = Rock | first1 = KL | year = 1996 | title = A new foreign policy: MHC class I molecules monitor the outside world | url = | journal = Immunol. Today | volume = 17 | issue = 3| pages = 131–7 | doi=10.1016/0167-5699(96)80605-0| pmid = 8820271 }}</ref>。此外，交叉呈遞對於使用蛋白質抗原的疫苗（比如[[腫瘤疫苗|腫瘤疫苗]]）接種來說也是必要的，因爲交叉呈遞可以誘導細胞免疫<ref>{{cite journal | last1 = Melief | first1 = CJ | year = 2003 | title = Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? | url = | journal = Eur J Immunol | volume = 33 | issue = 10| pages = 2645–54 | doi=10.1002/eji.200324341| pmid = 14515248 }}</ref>。

==參見==
*[[主要組織相容性複合物|主要組織相容性複合物]]
*[[細胞毒性T細胞|細胞毒性T細胞]]

==參考==
{{reflist}}

[[Category:免疫系統|Category:免疫系統]]